A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

NCT02468674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcopenia

Interventions

DRUG: bimagrumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals